title: Retrospective analysis of the tolerability and activity of lacosamide in patients with brain tumors: clinical article.
abstract: OBJECTIVE
  The object of this study was to determine the tolerability and activity of lacosamide in patients with brain tumors.
  
  
  METHODS
  The authors reviewed the medical records at 5 US academic medical centers with tertiary brain tumor programs, seeking all patients in whom a primary brain tumor had been diagnosed and who were taking lacosamide.
  
  
  RESULTS
  The authors identified 70 patients with primary brain tumors and reviewed seizure frequency and toxicities. The majority of the patients had gliomas (96%). Fifty-five (78%) had partial seizures only, and 12 (17%) had generalized seizures. Most of the patients (74%) were started on lacosamide because of recurrent seizures. Forty-six patients (66%) reported a decrease in seizure frequency, and 21 patients (30%) reported stable seizures. Most of the patients (54 [77%]) placed on lacosamide did not report any toxicities.
  
  
  CONCLUSIONS
  This retrospective analysis demonstrated that lacosamide was both well tolerated and active as an add-on antiepileptic drug (AED) in patients with brain tumors. Lacosamide's novel mechanism of action will allow for concurrent use with other AEDs, as documented by its activity across many different types of AEDs used in this patient population. Larger prospective studies are warranted.
authors: Department of Neurosciences, Moores Cancer Center, University of California, San Diego, La Jolla, California 92093-0819, USA. skesari@ucsd.edu
authors: Marlon G
authors: MG
authors: Saria
authors: Courtney
authors: C
authors: Corle
authors: Jethro
authors: J
authors: Hu
authors: Jeremy D
authors: JD
authors: Rudnick
authors: Surasak
authors: S
authors: Phuphanich
authors: Maciej M
authors: MM
authors: Mrugala
authors: Laura K
authors: LK
authors: Crew
authors: Daniela A
authors: DA
authors: Bota
authors: Beverly
authors: B
authors: Dan Fu
authors: Ryan Y
authors: RY
authors: Kim
authors: Tiffany
authors: T
authors: Brown
authors: Homira
authors: H
authors: Feely
authors: Joanne
authors: J
authors: Brechlin
authors: Bradley D
authors: BD
authors: Brown
authors: Jan
authors: J
authors: Drappatz
authors: Patrick Y
authors: PY
authors: Wen
authors: Clark C
authors: CC
authors: Chen
authors: Bob
authors: B
authors: Carter
authors: Jong Woo
authors: JW
authors: Lee
authors: Santosh
authors: S
authors: Kesari
mesh_terms: D000081:Acetamides / Q000009:adverse effects* / Q000627:therapeutic use*; D000328:Adult; D000927:Anticonvulsants / Q000009:adverse effects* / Q000627:therapeutic use*; D001932:Brain Neoplasms / Q000188:drug therapy*; D004305:Dose-Response Relationship, Drug; D004359:Drug Therapy, Combination; D005260:Female; D005500:Follow-Up Studies; D005909:Glioblastoma / Q000188:drug therapy; D006801:Humans; D000078334:Lacosamide; D008297:Male; D008875:Middle Aged; D015995:Prevalence; D012189:Retrospective Studies; D055502:Secondary Prevention; D012640:Seizures / Q000453:epidemiology / Q000517:prevention & control*; D016896:Treatment Outcome
chemical_list: D000081:Acetamides; D000927:Anticonvulsants; D000078334:Lacosamide